Welcome to our dedicated page for LSBPW SEC filings (Ticker: LSBPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LakeShore Biopharma Co., Ltd. files as a foreign private issuer, with Form 6-K reports documenting material events, governance matters, shareholder voting items, capital-structure disclosures, material agreements, and operating and financial results.
The company's filings also cover clinical or regulatory disclosures, security-structure matters, legal and arbitration developments involving affiliated biopharma entities, and its transition to the OTC market following a Nasdaq delisting.
LakeShore Biopharma has called an extraordinary general meeting of shareholders on June 19, 2026 in Beijing to vote on a previously announced going‑private merger with Oceanpine Skyline Inc. and its subsidiary.
If approved and completed, the merger would make the company a wholly owned subsidiary of Oceanpine Skyline Inc., its ordinary shares and warrants would stop trading on public quotation systems, and its securities would cease to be registered under the U.S. Exchange Act. Shareholders of record as of May 27, 2026 are entitled to vote, and the board, following a special committee’s unanimous recommendation, has resolved to recommend a FOR vote on the merger agreements and related transactions.
LakeShore Biopharma has called an extraordinary general meeting of shareholders on June 19, 2026 in Beijing to vote on a previously announced going‑private merger with Oceanpine Skyline Inc. and its subsidiary.
If approved and completed, the merger would make the company a wholly owned subsidiary of Oceanpine Skyline Inc., its ordinary shares and warrants would stop trading on public quotation systems, and its securities would cease to be registered under the U.S. Exchange Act. Shareholders of record as of May 27, 2026 are entitled to vote, and the board, following a special committee’s unanimous recommendation, has resolved to recommend a FOR vote on the merger agreements and related transactions.
LakeShore Biopharma’s major shareholders have amended their go‑private deal, sharply cutting the proposed cash payout to public investors. The Amended Merger Agreement reduces the per share merger consideration from US$0.90 to US$0.066, implying about US$1.3 million to buy out outstanding ordinary shares not held by rollover shareholders. The lead reporting person, Huaqin Xue, is deemed to beneficially own 21,021,332 ordinary shares, or 51.0% of the company based on 41,212,693 shares outstanding as of June 30, 2025. Several funds, including Oceanpine, Adjuvant, MSA Growth, Superstring and Epiphron, report smaller holdings below 2% each. Termination fees are also reduced to US$50,000 for the company and US$100,000 for the parent. If the merger closes, LakeShore Biopharma’s ordinary shares would be deregistered and cease trading on the OTC Pink Open Market.
LakeShore Biopharma’s major shareholders have amended their go‑private deal, sharply cutting the proposed cash payout to public investors. The Amended Merger Agreement reduces the per share merger consideration from US$0.90 to US$0.066, implying about US$1.3 million to buy out outstanding ordinary shares not held by rollover shareholders. The lead reporting person, Huaqin Xue, is deemed to beneficially own 21,021,332 ordinary shares, or 51.0% of the company based on 41,212,693 shares outstanding as of June 30, 2025. Several funds, including Oceanpine, Adjuvant, MSA Growth, Superstring and Epiphron, report smaller holdings below 2% each. Termination fees are also reduced to US$50,000 for the company and US$100,000 for the parent. If the merger closes, LakeShore Biopharma’s ordinary shares would be deregistered and cease trading on the OTC Pink Open Market.
LakeShore Biopharma entered into an amended merger agreement with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. for a going‑private transaction implying an equity value of approximately US$2.7 million. Each ordinary share will be cancelled for US$0.066 in cash, other than excluded and dissenting shares.
The new per‑share cash price, described as amended merger consideration, is reduced from US$0.90 to US$0.066 but represents premiums of about 46.7% to the March 24, 2026 closing price and 23.3% to the 10‑day volume‑weighted average price. Termination fees are cut to US$50,000 for the company and US$100,000 for the parent, and the termination date is extended to nine months from the amendment date.
The board, acting on the unanimous recommendation of a three‑member independent Special Committee, approved the amended deal and recommends shareholder approval. Rollover shareholders holding about 53.35% of voting rights agreed to support the merger. Closing is currently expected in the third quarter of 2026, after customary conditions and a shareholder vote. If completed, LakeShore Biopharma will become privately held and its shares will cease trading on the OTC Pink Open Market.
LakeShore Biopharma entered into an amended merger agreement with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. for a going‑private transaction implying an equity value of approximately US$2.7 million. Each ordinary share will be cancelled for US$0.066 in cash, other than excluded and dissenting shares.
The new per‑share cash price, described as amended merger consideration, is reduced from US$0.90 to US$0.066 but represents premiums of about 46.7% to the March 24, 2026 closing price and 23.3% to the 10‑day volume‑weighted average price. Termination fees are cut to US$50,000 for the company and US$100,000 for the parent, and the termination date is extended to nine months from the amendment date.
The board, acting on the unanimous recommendation of a three‑member independent Special Committee, approved the amended deal and recommends shareholder approval. Rollover shareholders holding about 53.35% of voting rights agreed to support the merger. Closing is currently expected in the third quarter of 2026, after customary conditions and a shareholder vote. If completed, LakeShore Biopharma will become privately held and its shares will cease trading on the OTC Pink Open Market.
LakeShore Biopharma Co., Ltd. director and President/CBO Shao Hui David filed an initial ownership report showing holdings of Ordinary Shares. He directly owns 133,360 Ordinary Shares and is also deemed to beneficially own 180,278 Ordinary Shares held indirectly through Mountainview Investment Holdings LLC, which he wholly controls as a director.
LakeShore Biopharma Co., Ltd. director and President/CBO Shao Hui David filed an initial ownership report showing holdings of Ordinary Shares. He directly owns 133,360 Ordinary Shares and is also deemed to beneficially own 180,278 Ordinary Shares held indirectly through Mountainview Investment Holdings LLC, which he wholly controls as a director.
LakeShore Biopharma Co., Ltd. director and Chief Executive Officer Wang Xu reported an initial holding of a stock option in a Form 3. The option gives the right to acquire 203,464 ordinary shares at an exercise price of $1.225 per share and expires on December 13, 2034.
According to the vesting terms, 25% of the underlying shares vest on December 31, 2024, and the remaining 75% vest in three equal annual installments on each anniversary of the December 13, 2024 grant date, contingent on continued service with the company.
LakeShore Biopharma Co., Ltd. director and Chief Executive Officer Wang Xu reported an initial holding of a stock option in a Form 3. The option gives the right to acquire 203,464 ordinary shares at an exercise price of $1.225 per share and expires on December 13, 2034.
According to the vesting terms, 25% of the underlying shares vest on December 31, 2024, and the remaining 75% vest in three equal annual installments on each anniversary of the December 13, 2024 grant date, contingent on continued service with the company.
LakeShore Biopharma Co., Ltd. director Xue Linnan has filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing establishes their status as a director and formally begins periodic ownership reporting, but does not itself reflect any buy or sell transaction.
LakeShore Biopharma Co., Ltd. director Xue Linnan has filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing establishes their status as a director and formally begins periodic ownership reporting, but does not itself reflect any buy or sell transaction.
LakeShore Biopharma Co., Ltd. director and Chief Financial Officer Yu Rui reported initial beneficial ownership of a share option covering 203,464 underlying Ordinary Shares. The option has an exercise price of $1.225 per share and expires on December 13, 2034.
According to the vesting terms, 25% of the underlying shares vest on December 31, 2024, and the remaining 75% vest in three equal annual installments on each anniversary of the December 13, 2024 grant date, subject to Yu Rui’s continued service to the company. The filing does not reflect any purchase or sale of shares, only this option holding.
LakeShore Biopharma Co., Ltd. director and Chief Financial Officer Yu Rui reported initial beneficial ownership of a share option covering 203,464 underlying Ordinary Shares. The option has an exercise price of $1.225 per share and expires on December 13, 2034.
According to the vesting terms, 25% of the underlying shares vest on December 31, 2024, and the remaining 75% vest in three equal annual installments on each anniversary of the December 13, 2024 grant date, subject to Yu Rui’s continued service to the company. The filing does not reflect any purchase or sale of shares, only this option holding.
LakeShore Biopharma Co., Ltd. director Pan Yue has filed an initial Form 3, which is the required first ownership report for company insiders. The filing identifies Pan Yue as a director but, in the provided data, does not show any reportable transactions or derivative positions.
LakeShore Biopharma Co., Ltd. director Pan Yue has filed an initial Form 3, which is the required first ownership report for company insiders. The filing identifies Pan Yue as a director but, in the provided data, does not show any reportable transactions or derivative positions.
LakeShore Biopharma Co., Ltd. director Shao Chunyang filed a Form 3, which is an initial statement of beneficial ownership for insiders. This filing reports no share purchases, sales, gifts, or other equity transactions and shows no derivative positions or holding entries for this reporting person.
LakeShore Biopharma Co., Ltd. director Shao Chunyang filed a Form 3, which is an initial statement of beneficial ownership for insiders. This filing reports no share purchases, sales, gifts, or other equity transactions and shows no derivative positions or holding entries for this reporting person.
LakeShore Biopharma Co., Ltd. filed an initial Form 3 to report the beneficial ownership status of director Zhao Jutao. The filing lists Zhao as a board member and indicates no reported transactions or holdings in either common stock or derivative securities at this time.
LakeShore Biopharma Co., Ltd. filed an initial Form 3 to report the beneficial ownership status of director Zhao Jutao. The filing lists Zhao as a board member and indicates no reported transactions or holdings in either common stock or derivative securities at this time.